Abstract
Background Tobacco smoking remains the leading cause of preventable death and disease worldwide. Digital interventions delivered through smartphones offer a promising alternative to traditional methods, but little is known about their effectiveness.
Objective Our objective was to test the effectiveness of Quit Genius, a novel digital therapeutic intervention for smoking cessation.
Methods A two-arm, single-blinded, parallel-group randomized controlled trial design was used. Participants were recruited via referrals from primary care practices and social media advertisements in the UK. 556 Adult smokers (aged ≥18 years), smoking at least five cigarettes a day for the past year were recruited. 530 were included for the final analysis. Participants were randomized to one of two interventions. Treatment consisted of a digital therapeutic intervention for smoking cessation consisting of a smartphone application delivering cognitive behavioral therapy content, one-to-one coaching, craving tools and tracking capabilities. The control intervention was Very Brief Advice along the Ask, Advise, Act model. All participants were offered nicotine replacement therapy for three months. A random half of each arm was assigned a carbon monoxide (CO) device for biochemical verification. Outcomes were self-reported via phone or online. The primary outcome was self-reported 7-day point prevalence abstinence at 4-weeks post quit date.
Results 556 participants were randomized (treatment n=277, control n=279). The intention-to-treat analysis included 530 participants (n=265 in each arm; 11 excluded for randomization before trial registration, and 15 for protocol violations at baseline visit). By the quit date (an average 16 days after randomization) 89% (236/265) of those in the treatment arm were still actively engaged. At the time of primary outcome, 74% (196) of participants were still engaging with the app. At 4-weeks post-quit date, 45% (118) of participants in the treatment arm had not smoked in the preceding 7-days, compared to 29% (76) in control (risk ratio 1.55, 1.23-1.96, P = .0002; intention-to-treat, N=530). Self-reported 7-day abstinence agreed with CO measurement (CO <10 ppm) in 96% of cases (80/83) where CO readings were available. No harmful effects of the intervention were observed.
Conclusions The Quit Genius digital therapeutic intervention is a superior treatment in achieving smoking cessation four weeks post quit date compared to very brief advice.
Trial Registration The trial was registered in the ISRCTN database on December 18, 2018 (https://www.isrctn.com/ISRCTN65853476).
Competing Interest Statement
The study was funded by the company that produced the Quit Genius digital therapeutic intervention (Digital Therapeutics, Inc). PS is a paid statistical consultant. All other authors except Azeem Majeed received a salary from or own equity in Digital Therapeutics, Inc.
Clinical Trial
ISRCTN65853476
Funding Statement
The study was funded by the company that produced the Quit Genius digital therapeutic intervention (Digital Therapeutics, Inc). PS is a paid statistical consultant. All other authors except Azeem Majeed received a salary from or own equity in Digital Therapeutics, Inc.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Health and Social Care Research Ethics Committee A (HSC REC A; reference 18/NI/0171)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Clinical trial registration: ISRCTN registry, number ISRCTN65853476 (https://www.isrctn.com/ISRCTN65853476)
Data Availability
Data is available upon request
